Ignite Creation Date:
2024-05-05 @ 5:07 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00396799
Status:
COMPLETED
Last Update Posted:
2007-03-13
First Post:
2006-11-07
Brief Title:
Bioequivalence Study Of BazedoxifeneConjugated Estrogen Tablets In Postmenopausal Women
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
An Open-Label Single-Dose Randomized-to-Sequence 2-Period Crossover Pivotal Bioequivalence Study Between Bazedoxifene AcetateConjugated Estrogens Premarin Current Process and Bazedoxifene AcetateConjugated Estrogens Premarin New Process Tablets Administered to Healthy Postmenopausal Women
Status:
COMPLETED
Status Verified Date:
2007-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to evaluate the bioequivalence between bazedoxifeneconjugated estrogens tablets produced using the current manufacturing process to bazedoxifeneconjugated estrogens tablets produced using a new manufacturing process
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None